US equities · SEC fundamentals

AbbVie Inc.

ABBV · CIK 0001551152 · Pharmaceutical Preparations

Source: SEC EDGAR/XBRL

Revenue

USD

61.2B USD

Period data
PeriodValue
FY 202156.2B USD
FY 202258.1B USD
FY 202354.3B USD
FY 202456.3B USD
FY 202561.2B USD

Operating income

USD

15.1B USD

Period data
PeriodValue
FY 202117.9B USD
FY 202218.1B USD
FY 202312.8B USD
FY 20249.1B USD
FY 202515.1B USD

Net income

USD

4.2B USD

Period data
PeriodValue
FY 202111.5B USD
FY 202211.8B USD
FY 20234.9B USD
FY 20244.3B USD
FY 20254.2B USD

Total assets

USD

134B USD

Period data
PeriodValue
FY 2021146.5B USD
FY 2022138.8B USD
FY 2023134.7B USD
FY 2024135.2B USD
FY 2025134B USD

Equity

USD

-3.3B USD

Period data
PeriodValue
FY 202115.4B USD
FY 202217.3B USD
FY 202310.4B USD
FY 20243.3B USD
FY 2025-3.3B USD

Operating cash flow

USD

19B USD

Period data
PeriodValue
FY 202122.8B USD
FY 202224.9B USD
FY 202322.8B USD
FY 202418.8B USD
FY 202519B USD

Revenue growth

%

8.6%

Period data
PeriodValue
FY 202122.7%
FY 20223.3%
FY 2023-6.4%
FY 20243.7%
FY 20258.6%

Operating income growth

%

65%

Period data
PeriodValue
FY 202157.7%
FY 20221.1%
FY 2023-29.6%
FY 2024-28.4%
FY 202565%

Net income growth

%

-1.2%

Period data
PeriodValue
FY 2021150%
FY 20222.5%
FY 2023-58.9%
FY 2024-12%
FY 2025-1.2%

Operating margin

%

24.6%

Period data
PeriodValue
FY 202131.9%
FY 202231.2%
FY 202323.5%
FY 202416.2%
FY 202524.6%

Net margin

%

6.9%

Period data
PeriodValue
FY 202120.5%
FY 202220.4%
FY 20239%
FY 20247.6%
FY 20256.9%

Return on assets

%

3.1%

Period data
PeriodValue
FY 20217.8%
FY 20228.3%
FY 20233.6%
FY 20243.2%
FY 20253.1%

Debt/Equity

x

No applicable data available

Period data
PeriodValue
FY 2021N/A
FY 2022N/A
FY 2023N/A
FY 2024N/A
FY 2025N/A